

FOR IMMEDIATE RELEASE



**PERTHERA TO HOST A BREAKFAST SYMPOSIUM
AT THE 2018 ASCO ANNUAL MEETING**

McLean, VA, May 22, 2018– Perthera, Inc., the leading Therapeutics Intelligence Company™, will be hosting a networking breakfast and educational session on Monday, June 4th from 6:30 – 7:30 a.m. for attendees of the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. The breakfast symposium will be held in the Regency D ballroom of the Hyatt Regency McCormick Place, directly adjacent to the McCormick Place.

“We are very excited to host this breakfast symposium at the 2018 ASCO Annual Meeting. With this event we hope to give ASCO attendees more information about who we are and what we do, and the good we can do for oncology patients.” Neal G. Koller, President & CEO, Perthera, Inc.

The breakfast symposium will feature 3 speakers:

Michael Pishvaian, M.D., Ph.D. presenting: *The Perthera Experience of a Comprehensive Case Review and Integration of Multi-omic Molecular Testing for 640 Cancer Patients Through the KYT Program*
Chief Medical Officer at Perthera, Inc.
Director, Phase I Clinical Program
Co-Director, Ruesch Center Pancreatic Cancer Program
Lombardi Cancer Center, Georgetown University, Washington DC

Jonathan Brody, Ph.D. presenting: *Integrating the Perthera Report into a High Volume Practice of Pancreatic Cancer Patients*
Director, Surgical Research
Co-Director, Jefferson Pancreas, Biliary and Related Cancer Center
Thomas Jefferson University, Philadelphia PA

Anthony Conley, M.D. presenting: *Initial Experience with the Perthera Report in our Cancer Clinic*
Assistant Professor, Department of Sarcoma Medical Oncology
The University of Texas MD Anderson Cancer Center, Houston TX

The 2018 ASCO Annual Meeting will be held at the McCormick Place Convention Center in Chicago from June 1st – 5th, and will host over 25,000 oncology professionals from around the world. In addition to the networking breakfast meeting, Perthera will be exhibiting in booth #16024 and have executives on hand during the conference to meet personally with attendees interested in learning more about our role in personalized medicine for cancer treatment.

ABOUT PERTHERA, INC.:

Perthera is the leading Therapeutic Intelligence Company advancing precision medicine through its Perthera Report™, which precisely matches cancer patients with multiple therapeutic options ranked by highest probability of best outcome.

www.perthera.com

###

Safe Harbor Statement:

The statements in the press release that relate to Perthera, Inc. (the “Company”) expectations with regard to the future impact on the Company’s results from new products in development and any other statements not constituting historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties which could cause the Company’s actual operating results, performance, business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.